Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neurogene ( (NGNE) ) just unveiled an announcement.
Neurogene Inc. reported positive interim data from its NGN-401 Phase 1/2 gene therapy trial for Rett syndrome, showing significant developmental gains across multiple domains for participants. The company has initiated its Embolden registrational trial and expects full enrollment within three to six months, supported by a strong financial position with cash reserves projected to last until the first quarter of 2028.
The most recent analyst rating on (NGNE) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Neurogene stock, see the NGNE Stock Forecast page.
Spark’s Take on NGNE Stock
According to Spark, TipRanks’ AI Analyst, NGNE is a Underperform.
Neurogene’s overall score is primarily influenced by its financial performance, which is challenged by zero revenues and significant net losses. While the stock shows some technical strength, the high beta and potential overbought conditions pose risks. The valuation reflects the speculative nature of investing in an early-stage biotech firm.
To see Spark’s full report on NGNE stock, click here.
More about Neurogene
Neurogene Inc. is a clinical-stage company focused on developing genetic medicines for patients and families affected by rare neurological diseases. The company’s primary focus is on gene therapy solutions, particularly targeting conditions like Rett syndrome.
Average Trading Volume: 201,488
Technical Sentiment Signal: Buy
Current Market Cap: $443.6M
See more data about NGNE stock on TipRanks’ Stock Analysis page.